Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Zabel, M, Willems, R, Lubinski, A, Bauer, A, Brugada, J, Conen, D, Flevari, P, Hasenfuß, G, Svetlosak, M, Huikuri, HV, Malik, M, Pavlović, N, Schmidt, G, Sritharan, R, Schlögl, S, Szavits-Nossan, J, Traykov, V, Tuinenburg, AE, Willich, SN, Harden, M, Friede, T, Svendsen, JH, Sticherling, C, Merkely, B & EU-CERT-ICD Study Investigators 2020, 'Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study' European Heart Journal, bind 41, nr. 36, s. 3437-3447. https://doi.org/10.1093/eurheartj/ehaa226

APA

CBE

Zabel M, Willems R, Lubinski A, Bauer A, Brugada J, Conen D, Flevari P, Hasenfuß G, Svetlosak M, Huikuri HV, Malik M, Pavlović N, Schmidt G, Sritharan R, Schlögl S, Szavits-Nossan J, Traykov V, Tuinenburg AE, Willich SN, Harden M, Friede T, Svendsen JH, Sticherling C, Merkely B, EU-CERT-ICD Study Investigators. 2020. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. European Heart Journal. 41(36):3437-3447. https://doi.org/10.1093/eurheartj/ehaa226

MLA

Vancouver

Author

Zabel, Markus ; Willems, Rik ; Lubinski, Andrzej ; Bauer, Axel ; Brugada, Josep ; Conen, David ; Flevari, Panagiota ; Hasenfuß, Gerd ; Svetlosak, Martin ; Huikuri, Heikki V ; Malik, Marek ; Pavlović, Nikola ; Schmidt, Georg ; Sritharan, Rajevaa ; Schlögl, Simon ; Szavits-Nossan, Janko ; Traykov, Vassil ; Tuinenburg, Anton E ; Willich, Stefan N ; Harden, Markus ; Friede, Tim ; Svendsen, Jesper Hastrup ; Sticherling, Christian ; Merkely, Béla ; EU-CERT-ICD Study Investigators. / Clinical effectiveness of primary prevention implantable cardioverter-defibrillators : results of the EU-CERT-ICD controlled multicentre cohort study. I: European Heart Journal. 2020 ; Bind 41, Nr. 36. s. 3437-3447.

Bibtex

@article{991d36760fcc4d41b0171d5f1e9599fc,
title = "Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study",
abstract = "AIMS : The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter-Defibrillators (EU-CERT-ICD), a prospective investigator-initiated, controlled cohort study, was conducted in 44 centres and 15 European countries. It aimed to assess current clinical effectiveness of primary prevention ICD therapy.METHODS AND RESULTS : We recruited 2327 patients with ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and guideline indications for prophylactic ICD implantation. Primary endpoint was all-cause mortality. Clinical characteristics, medications, resting, and 12-lead Holter electrocardiograms (ECGs) were documented at enrolment baseline. Baseline and follow-up (FU) data from 2247 patients were analysable, 1516 patients before first ICD implantation (ICD group) and 731 patients without ICD serving as controls. Multivariable models and propensity scoring for adjustment were used to compare the two groups for mortality. During mean FU of 2.4 ± 1.1 years, 342 deaths occurred (6.3{\%}/years annualized mortality, 5.6{\%}/years in the ICD group vs. 9.2{\%}/years in controls), favouring ICD treatment [unadjusted hazard ratio (HR) 0.682, 95{\%} confidence interval (CI) 0.537-0.865, P = 0.0016]. Multivariable mortality predictors included age, left ventricular ejection fraction (LVEF), New York Heart Association class <III, and chronic obstructive pulmonary disease. Adjusted mortality associated with ICD vs. control was 27{\%} lower (HR 0.731, 95{\%} CI 0.569-0.938, P = 0.0140). Subgroup analyses indicated no ICD benefit in diabetics (adjusted HR = 0.945, P = 0.7797, P for interaction = 0.0887) or those aged ≥75 years (adjusted HR 1.063, P = 0.8206, P for interaction = 0.0902).CONCLUSION : In contemporary ICM/DCM patients (LVEF ≤35{\%}, narrow QRS), primary prophylactic ICD treatment was associated with a 27{\%} lower mortality after adjustment. There appear to be patients with less survival advantage, such as older patients or diabetics.",
keywords = "Implantable cardioverter-defibrillator, Mortality, Risk factors, Sudden cardiac death",
author = "Markus Zabel and Rik Willems and Andrzej Lubinski and Axel Bauer and Josep Brugada and David Conen and Panagiota Flevari and Gerd Hasenfu{\ss} and Martin Svetlosak and Huikuri, {Heikki V} and Marek Malik and Nikola Pavlović and Georg Schmidt and Rajevaa Sritharan and Simon Schl{\"o}gl and Janko Szavits-Nossan and Vassil Traykov and Tuinenburg, {Anton E} and Willich, {Stefan N} and Markus Harden and Tim Friede and Svendsen, {Jesper Hastrup} and Christian Sticherling and B{\'e}la Merkely and {EU-CERT-ICD Study Investigators}",
note = "{\circledC} The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.",
year = "2020",
month = "9",
day = "21",
doi = "10.1093/eurheartj/ehaa226",
language = "English",
volume = "41",
pages = "3437--3447",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "36",

}

RIS

TY - JOUR

T1 - Clinical effectiveness of primary prevention implantable cardioverter-defibrillators

T2 - results of the EU-CERT-ICD controlled multicentre cohort study

AU - Zabel, Markus

AU - Willems, Rik

AU - Lubinski, Andrzej

AU - Bauer, Axel

AU - Brugada, Josep

AU - Conen, David

AU - Flevari, Panagiota

AU - Hasenfuß, Gerd

AU - Svetlosak, Martin

AU - Huikuri, Heikki V

AU - Malik, Marek

AU - Pavlović, Nikola

AU - Schmidt, Georg

AU - Sritharan, Rajevaa

AU - Schlögl, Simon

AU - Szavits-Nossan, Janko

AU - Traykov, Vassil

AU - Tuinenburg, Anton E

AU - Willich, Stefan N

AU - Harden, Markus

AU - Friede, Tim

AU - Svendsen, Jesper Hastrup

AU - Sticherling, Christian

AU - Merkely, Béla

AU - EU-CERT-ICD Study Investigators

N1 - © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

PY - 2020/9/21

Y1 - 2020/9/21

N2 - AIMS : The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter-Defibrillators (EU-CERT-ICD), a prospective investigator-initiated, controlled cohort study, was conducted in 44 centres and 15 European countries. It aimed to assess current clinical effectiveness of primary prevention ICD therapy.METHODS AND RESULTS : We recruited 2327 patients with ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and guideline indications for prophylactic ICD implantation. Primary endpoint was all-cause mortality. Clinical characteristics, medications, resting, and 12-lead Holter electrocardiograms (ECGs) were documented at enrolment baseline. Baseline and follow-up (FU) data from 2247 patients were analysable, 1516 patients before first ICD implantation (ICD group) and 731 patients without ICD serving as controls. Multivariable models and propensity scoring for adjustment were used to compare the two groups for mortality. During mean FU of 2.4 ± 1.1 years, 342 deaths occurred (6.3%/years annualized mortality, 5.6%/years in the ICD group vs. 9.2%/years in controls), favouring ICD treatment [unadjusted hazard ratio (HR) 0.682, 95% confidence interval (CI) 0.537-0.865, P = 0.0016]. Multivariable mortality predictors included age, left ventricular ejection fraction (LVEF), New York Heart Association class <III, and chronic obstructive pulmonary disease. Adjusted mortality associated with ICD vs. control was 27% lower (HR 0.731, 95% CI 0.569-0.938, P = 0.0140). Subgroup analyses indicated no ICD benefit in diabetics (adjusted HR = 0.945, P = 0.7797, P for interaction = 0.0887) or those aged ≥75 years (adjusted HR 1.063, P = 0.8206, P for interaction = 0.0902).CONCLUSION : In contemporary ICM/DCM patients (LVEF ≤35%, narrow QRS), primary prophylactic ICD treatment was associated with a 27% lower mortality after adjustment. There appear to be patients with less survival advantage, such as older patients or diabetics.

AB - AIMS : The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter-Defibrillators (EU-CERT-ICD), a prospective investigator-initiated, controlled cohort study, was conducted in 44 centres and 15 European countries. It aimed to assess current clinical effectiveness of primary prevention ICD therapy.METHODS AND RESULTS : We recruited 2327 patients with ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and guideline indications for prophylactic ICD implantation. Primary endpoint was all-cause mortality. Clinical characteristics, medications, resting, and 12-lead Holter electrocardiograms (ECGs) were documented at enrolment baseline. Baseline and follow-up (FU) data from 2247 patients were analysable, 1516 patients before first ICD implantation (ICD group) and 731 patients without ICD serving as controls. Multivariable models and propensity scoring for adjustment were used to compare the two groups for mortality. During mean FU of 2.4 ± 1.1 years, 342 deaths occurred (6.3%/years annualized mortality, 5.6%/years in the ICD group vs. 9.2%/years in controls), favouring ICD treatment [unadjusted hazard ratio (HR) 0.682, 95% confidence interval (CI) 0.537-0.865, P = 0.0016]. Multivariable mortality predictors included age, left ventricular ejection fraction (LVEF), New York Heart Association class <III, and chronic obstructive pulmonary disease. Adjusted mortality associated with ICD vs. control was 27% lower (HR 0.731, 95% CI 0.569-0.938, P = 0.0140). Subgroup analyses indicated no ICD benefit in diabetics (adjusted HR = 0.945, P = 0.7797, P for interaction = 0.0887) or those aged ≥75 years (adjusted HR 1.063, P = 0.8206, P for interaction = 0.0902).CONCLUSION : In contemporary ICM/DCM patients (LVEF ≤35%, narrow QRS), primary prophylactic ICD treatment was associated with a 27% lower mortality after adjustment. There appear to be patients with less survival advantage, such as older patients or diabetics.

KW - Implantable cardioverter-defibrillator

KW - Mortality

KW - Risk factors

KW - Sudden cardiac death

UR - http://www.scopus.com/inward/record.url?scp=85088901766&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehaa226

DO - 10.1093/eurheartj/ehaa226

M3 - Journal article

VL - 41

SP - 3437

EP - 3447

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 36

ER -

ID: 60076231